betes: Management of blood glucose.NICE Inherited Clinical Guideline G.London: NICE (Ref. no. N0128).2002 [cited 2003 Nov 25]. Availablefrom: http://www.nice.org.uk/cat.asp?c=36733

4. Gale EAM. A randomized, controlledtrial comparing insulin lispro withhuman soluble insulin in patientswith Type 1 diabetes on intensifiedinsulin therapy. Diabetic Med 2000;17(3): 209–214.

5. Garg SK, Carmain JA, Braddy KC, etal. Pre-meal insulin analogue insulinlispro vs Humulin (registered trademark) insulin treatment in youngsubjects with Type 1 diabetes. DiabeticMed 1996; 13(1): 47–52.

6. Pfutzner A, Kustner E, Forst T, et al.Intensive insulin therapy with insulinlispro in patients with type 1 diabetesreduces the frequency of hypo-glycemic episodes. Exp ClinEndocrinol Diabetes 1996; 104(1):25–30.

7. Holleman F, Schmitt H, Rottiers R, etal. Reduced frequency of severehypoglycemia and coma in well-con-trolled IDDM patients treated withinsulin lispro. Diabetes Care 1997;20(12): 1827–1832.

8. Anderson JH Jr, Brunelle RL,Keohane P, et al. Mealtime treatmentwith insulin analog improves post-prandial hyperglycemia and hypo-glycemia in patients with non-insulin-dependent diabetes mellitus.Multicenter Insulin Lispro Study

Group. Arch Intern Med 1997;157(11): 1249–1255.

9. Anderson JH Jr, Brunelle RL,Koivisto VA, et al. Reduction of post-prandial hyperglycemia and fre-quency of hypoglycemia in IDDMpatients on insulin-analog treatment.Multicenter Insulin Lispro StudyGroup. Diabetes 1997; 46(2): 265–270.

10.Herz M, Arora V, Campaigne BN, etal. Humalog Mix25 improves 24-hour plasma glucose profiles com-pared with the human insulin mix-ture 30/70 in patients with type 2 dia-betes mellitus. S African Med J 2003;8(1): 12–16.

11.Mattoo V, Milicevic Z, Malone JK, etal. A comparison of insulin lispromix25 and human insulin 30/70 inthe treatment of type 2 diabetes dur-ing Ramadan. Diabetes Research ClinPract 2003; 59: 137–143.

12.Herz M, Profozic V, Arora V, et al.Effects of a fixed mixture of 25%insulin lispro and 75% NPL onplasma glucose during and aftermoderate physical exercise inpatients with type 2 diabetes. CurrentMed Research Opinion 2002; 18(4):188–193.

13.Roach P, Strack T, Arora V, et al.Improved glycaemic control with theuse of self-prepared mixtures ofinsulin lispro and insulin lispro prot-amine suspension in patients withtypes 1 and 2 diabetes. Int J Clin Pract2001; 55(3): 177–182.

14.Malone JK, Yang H, Woodworth JR, et

al. Humalog Mix25 offers bettermealtime control in patients withtype 1 or type 2 diabetes. Diabetes &Metabolism 2000; 26(6): 481–487.

15.Malone JK, Woodworth JR, Arora V,et al. Improved postprandial glycemiccontrol with Humalog Mix75/25after a standard test meal in patientswith type 2 diabetes mellitus. ClinTherapeutics 2000; 22(2): 222–230.

16. Janssen MM, Snoek FJ, Masurel N, etal. Optimized basal-bolus therapyusing a fixed mixture of 75% lisproand 25% NPL insulin in type 1 dia-betes patients: no favorable effectson glycemic control, physiologicalresponses to hypoglycemia, well-being, or treatment satisfaction.Diabetes Care 2000; 23(5): 629–633.

17.Roach P, Yue L, Arora V. HumalogMix25 Study Group: Improved post-prandial glycaemic control duringtreatment with Humalog Mix25, anovel protamine-based insulin lisproformulation. Diabetes Care 1999;22(8): 1258–1261.

18.Roach P, Trautmann M, Arora V, et al.Improved postprandial blood glu-cose control and reduced nocturnalhypoglycemia during treatment withtwo novel insulin lispro-protamineformulations, insulin lispro Mix25and insulin lispro Mix50. ClinTherapeutics 1999; 21(3): 523–534.

19.Koivisto VA, Tuominen JA, Ebeling P.Lispro Mix25 insulin as a premealtherapy in type 2 diabetes patients.Diabetes Care 1999; 22: 459–462.

Pract Diab Int November/December 2004 Vol. 21 No. 9 Copyright © 2004 John Wiley & Sons, Ltd. 333

AUDIT

Clinical outcomes of switching from conventional insulin to Humalog Mix 25

RCN Paediatricand AdolescentDiabetes GroupThe RCN Paediatric and AdolescentDiabetes Group welcomes the appear-ance of two new publications, which wehope will have a positive impact on ourwork: firstly, the NICE (NationalInstitute for Clinical Excellence) guide-lines for diagnosis and management oftype 1 diabetes in children and youngpeople (published July 2004); and sec-ondly, the Children’s National Service

Framework (published September2004). These long-awaited documentswill help to strengthen the case foradditional resources in order to rein-force our continued efforts to drive upthe standard of care offered to all ouryoung patients.

At the time of writing, the Group islooking forward to our AnnualConference, to be held at theManchester Conference Centre at theend of November. The Conference hasgone from strength to strength overthe years, offering all those involved inthe care of children and young peoplewith diabetes a great opportunity to

hear first class speakers on topicalissues, and to network with colleagues.A report is scheduled to appear in thenext issue.

Report by Jane Bramwell, PaediatricDiabetes Nurse Specialist, Royal GwentHospital, and Publicity Officer of RCNPaediatric and Adolescent Diabetes Group

The Royal College of Nursing:The Voice of Nursing20 Cavendish Square, London W1M 0AB. Tel: 020 7409 3333 Fax: 020 7647 3435

ROYAL

COLLEGE OF

NURSING

RCN News

Aud Davies 19.04.qxp 24/11/04 2:24 pm Page 5